本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司（以下简称"公司"）第三届董事会第二十次会 议于 2023 年 9 月 11 日以现场结合通讯方式召开。本次会议的通知和材料已于 2023 年 9 月 6 日由董事会办公室提交全体董事。会议应出席董事 7 人，实际出 席董事 7 人。会议由董事长张海先生召集和主持，会议的召开符合《公司法》及 《公司章程》的规定。 证券代码：603439 证券简称：贵州三力 公告编号：2023-059 贵州三力制药股份有限公司 第三届董事会第二十次会议决议公告 会议审议并形成以下决议： 贵州三力制药股份有限公司董事会 2023 年 9 月 12 日 《贵州三力制药股份有限公司与全资子公司共同对外投资参与设立有限合 伙企业的公告》全文刊载于上海证券交易所网站（http://www.sse.com.cn）， 投资者可查询详细内容。 特此公告。 一、审议通过了《关于公司与全资子公司共同对外投资参与设立有限合伙企 业的议案》 表决结果：7 票同意、0 票反对、0 票弃权。 ...

公司于 2023 年 9 月 8 日以网络互动方式召开 2023 年半年度业绩说明会，就 投资者关心的公司经营业绩、财务状况、发展战略规划等事项与投资者进行了沟 通和交流，现将有关事项公告如下： 证券代码：603439 证券简称：贵州三力 编号：2023-058 贵州三力制药股份有限公司 关于2023年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、投资者说明会召开情况 本次投资者说明会于 2023 年 9 月 8 日（星期五）下午 14:00-15:00 在上海 证 券 交 易 所 " 上 海 证 券 交 易 所 上 证 路 演 中 心 "（ 网 址 ： http://roadshow.sseinfo.com/）以网络互动方式召开。关于本次业绩说明会的 召开事项，公司于 2023 年 8 月 31 日在上海证券交易所网站披露了《贵州三力制 药股份有限公司关于召开 2023 年半年度业绩说明会的公告》（2023-056）。 公司董事长、总经理张海先生，公司副董事长、董事会秘书张千帆先生，公 ...

证券代码：603439 证券简称：贵州三力 公告编号：2023-057 贵州三力制药股份有限公司 关于公司控股股东之一致行动人收到贵州证监局 警示函的公告 根据《上市公司股东、董监高减持股份的若干规定》(证监会公告〔2017〕9 号)第十四条的规定，我局决定对你采取出具警示函的行政监管措施，并记入证 券期货市场诚信档案。你应认真汲取教训，加强证券法律法规学习，切实规范上 市公司股份减持行为，杜绝此类违规行为再次发生，并在收到本决定书之日起 10 1 日内向我局报送书面报告。 如果对本监督管理措施不服，可以在收到本决定书之日起 60 日内向中国证 券监督管理委员会提出行政复议申请，也可以在收到本决定书之日起 6 个月内向 有管辖权的人民法院提起诉讼。复议与诉讼期间，上述监督管理措施不停止执行。" 二、其他情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司（以下简称"公司"）控股股东之一致行动人王 惠英女士于近日收到中国证券监督管理委员会贵州监管局出具的《关于对王惠英 采取出具警示函措施的决定》（〔 ...

Financial Performance - Guizhou Sanli reported a significant increase in revenue, achieving a total of 500 million yuan in the first half of 2023, representing a 20% year-over-year growth[12]. - The company’s net profit for the same period reached 100 million yuan, marking a 15% increase compared to the previous year[12]. - The company's operating revenue for the first half of 2023 reached ¥630,661,743.72, representing a 46.74% increase compared to ¥429,787,883.94 in the same period last year[19]. - Net profit attributable to shareholders was ¥100,946,066.48, up 57.75% from ¥63,991,890.74 year-on-year[19]. - The basic earnings per share increased to ¥0.25, a 56.25% rise from ¥0.16 in the previous year[20]. - The weighted average return on equity rose to 7.87%, an increase of 1.87 percentage points compared to 6.00% in the same period last year[20]. - The net cash flow from operating activities was ¥92,853,823.32, reflecting a 20.03% increase from ¥77,357,428.57 in the previous year[19]. - The company has outlined a performance guidance of 10-15% revenue growth for the full year 2023[12]. Market Expansion and Product Development - User data indicates that the customer base expanded by 30%, with over 1 million new users acquired in the first half of 2023[12]. - Guizhou Sanli plans to launch three new products in the second half of 2023, focusing on innovative healthcare solutions[12]. - Market expansion efforts include entering two new provinces, targeting a 10% increase in market share by the end of 2023[12]. - The company plans to expand its market reach and enhance its product offerings in response to the growing demand for throat-related medications[20]. - The core products, including the throat spray for adults and children, saw a significant increase in market demand, contributing to the revenue growth[20]. Research and Development - The company is investing 50 million yuan in R&D for new technologies aimed at enhancing product efficacy and safety[12]. - The company is focused on the research and development of traditional Chinese medicine, supported by recent government policies aimed at promoting the industry[24][25]. - Research and development expenses surged by 323.18% to CNY 10.41 million, reflecting increased investment in R&D projects[50]. - The company has initiated multi-center clinical research for its core product, the Gynecological Reconstruction Pill, in 23 hospitals, enhancing its medical evidence chain[45]. Supply Chain and Production - The company has established long-term stable relationships with suppliers for key raw materials, ensuring a reliable supply chain[29]. - The procurement process involves selecting qualified suppliers based on quality, price, and service, with a minimum of two suppliers for each raw material to ensure stability[29]. - The company adopts a "sales-driven production" model, adjusting production plans based on market demand and sales forecasts to optimize efficiency[30]. - The company has implemented a comprehensive quality control system in compliance with the latest GMP standards, ensuring product quality throughout the production process[32]. Corporate Governance and Compliance - The board confirmed the accuracy and completeness of the financial report, ensuring no misleading statements were made[12]. - No significant risks were identified that could impact the company's operations during the reporting period[12]. - The company has not proposed any profit distribution or capital reserve transfer plans for the first half of 2023[72]. - The company has committed to maintaining transparency regarding its shareholding changes and compliance with regulatory requirements[96]. Environmental Responsibility - The company has established a wastewater treatment plant with a capacity of 100 tons per day, achieving COD and ammonia nitrogen removal rates of over 98%[75]. - The company operates two sets of 4-ton natural gas boilers, which meet emission standards after dust purification[76]. - The company has a dedicated hazardous waste storage facility, managed by specialized personnel, ensuring compliance with hazardous waste storage pollution control standards[76]. - The company has committed to reducing carbon emissions through resource recycling and tree planting initiatives[90]. Shareholder Information - The company reported a significant decrease in restricted shares, with 247,054,640 shares reduced, resulting in a total of 1,524,000 restricted shares remaining[120]. - The total number of shares after the changes is 409,862,216, with 99.63% being unrestricted shares[120]. - The company has committed to repurchasing all newly issued shares and transferring restricted shares if any false statements are found in the prospectus, with a repurchase price not lower than the issuance price plus interest[12]. - The controlling shareholder, Zhang Hai, has pledged not to engage in any competitive activities with the company or its subsidiaries[99].

证券代码：603439 证券简称：贵州三力 公告编号：2023-056 贵州三力制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 06 日(星期三)至 09 月 07 日(星期四)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zhangqf@gz-sa nli.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上 半年经营成果、财务状况，公司计划于 2023 年 09 月 08 日下午 14:00-15:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投 ...

证券代码：603439 证券简称：贵州三力 公告编号：2023-037 贵州三力制药股份有限公司 关于2022年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于2023年5月17日以网络远程方式召开2022年度贵州辖区上市公司业绩 说明会暨投资者集体接待日活动，就投资者关心的公司经营业绩、财务状况等事 项与投资者进行了沟通和交流，现将有关事项公告如下： 一、投资者说明会召开情况 本次业绩说明会暨投资者集体接待日活动于2023年5月17日(星期三)下午 15:30-17:30在全景服务平台(网址：http://rs.p5w.net)以网络远程方式召开。关于 本次投资者说明会的召开事项，公司于2023年5月9日在上海证券交易所网站披露 了《贵州三力制药股份有限公司关于参加2022年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动的公告》(2023-034)。 公司董事长、总经理张海先生，公司董事会秘书张千帆先生，公司财务总监 张红玉女士参加了本次投资者说 ...

证券代码：603439 证券简称：贵州三力 公告编号：2023-034 贵州三力制药股份有限公司 关于参加 2022 年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日(星期三)下午 15:30-17:00 会议召开地点：全景服务平台（网址：http://rs.p5w.net） 会议召开方式：网络远程方式 会议问题征集：提问通道自本公告发出之日起开放至2023年5月15日截止， 通过微信关注"贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）于 2023 年 4 月 15 日在上 海证券交易所网站（http://www.sse.com.cn）披露了《公司 2022 年年度报告》。 为加强上市公司与投资者的交流互动，便于投资者进一步了解公司 2022 年度经 营情况及其他关切问题，在贵州证监局指导下，贵州证券 ...

一、业绩说明会的安排 召开时间：2023 年 5 月 17 日 15:30-17:00 召开方式：网络远程方式 证券代码：603439 证券简称：贵州三力 公告编号：2023-034 贵州三力制药股份有限公司 关于参加 2022 年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议问题征集：提问通道自本公告发出之日起开放至2023年5月15日截止， 通过微信关注"贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）于 2023 年 4 月 15 日在上 海证券交易所网站（http://www.sse.com.cn）披露了《公司 2022 年年度报告》。 为加强上市公司与投资者的交流互动，便于投资者进一步了解公司 2022 年度经 营情况及其他关切问题，在贵州证监局指导下，贵州证券业协会联合深圳市全景 网络有限公司举办 2022 年度贵州辖区上市公司业 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥348,977,589.51, representing a year-on-year increase of 119.92%[5] - Net profit attributable to shareholders was ¥54,932,724.23, reflecting a growth of 131.49% compared to the same period last year[5] - The basic earnings per share (EPS) was ¥0.13, an increase of 116.67% year-on-year[5] - Total revenue for Q1 2023 reached ¥348,977,589.51, a significant increase of 120.3% compared to ¥158,680,694.88 in Q1 2022[19] - Operating profit for Q1 2023 was ¥63,384,620.11, up 160.5% from ¥24,345,225.45 in Q1 2022[20] - Net profit for Q1 2023 amounted to ¥53,396,249.70, representing a growth of 167.0% compared to ¥19,979,984.26 in Q1 2022[20] - Total comprehensive income for the first quarter of 2023 was CNY 54,932,724.23, compared to CNY 23,729,640.91 in the same period of 2022, representing a significant increase[21] - Basic and diluted earnings per share for Q1 2023 were CNY 0.13, up from CNY 0.06 in Q1 2022, indicating a 116.67% increase[21] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥1,889,405,604.26, up 4.01% from the end of the previous year[6] - Total assets as of March 31, 2023, were ¥1,889,405,604.26, an increase from ¥1,816,619,420.45 at the end of 2022[16] - Current assets totaled ¥1,097,464,914.71, down from ¥1,172,058,092.46 at the end of 2022, primarily due to a decrease in cash and cash equivalents[16] - Non-current assets increased to ¥791,940,689.55 from ¥644,561,327.99, driven by growth in intangible assets and goodwill[16] - Total liabilities decreased to ¥528,010,349.39 from ¥578,398,211.98, reflecting a reduction in current liabilities[17] - The company’s equity attributable to shareholders increased to ¥1,295,605,285.33 from ¥1,239,043,767.96, reflecting retained earnings growth[17] Cash Flow - The net cash flow from operating activities was negative at -¥1,351,706.77, a decline of 102.44% year-on-year due to increased expenses related to sales growth[5][8] - Cash inflow from operating activities was CNY 337,896,983.09 in Q1 2023, compared to CNY 221,104,972.51 in Q1 2022, reflecting a growth of 52.93%[23] - Cash outflow from operating activities totaled CNY 339,248,689.86 in Q1 2023, compared to CNY 165,670,243.07 in Q1 2022, resulting in a net cash flow from operating activities of -CNY 1,351,706.77[24] - Cash inflow from investment activities was CNY 64,394,206.67 in Q1 2023, compared to CNY 48,843,199.90 in Q1 2022, marking a 32% increase[24] - Cash outflow from investment activities was CNY 176,471,434.73 in Q1 2023, down from CNY 194,466,733.56 in Q1 2022, indicating a decrease of 9.25%[24] - Net cash flow from investment activities was -CNY 112,077,228.06 in Q1 2023, an improvement from -CNY 145,623,533.66 in Q1 2022[24] - Cash and cash equivalents at the end of Q1 2023 were CNY 455,166,574.82, slightly up from CNY 454,854,470.68 at the end of Q1 2022[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,467[11] Research and Development - The company reported a significant increase in R&D expenses, which rose to ¥5,014,006.28 from ¥1,024,157.45 in Q1 2022, indicating a focus on innovation[20] Other Information - The company did not execute any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[21] - Non-recurring gains and losses totaled ¥1,215,311.30 for the quarter[9] - The company experienced significant growth in product sales, which was the primary driver for the increase in revenue and net profit[8]

证券代码：603439 证券简称：贵州三力 公告编号：2022-024 贵州三力制药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 19 日(星期三)至 4 月 23 日(星期日)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zhangqf@gz-sanli. com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 贵州三力制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 15 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 4 月 24 日下午 14:00-15:00 举行 2022 年 度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资 ...